Literature DB >> 28140338

A Monte Carlo study of I-125 prostate brachytherapy with gold nanoparticles: dose enhancement with simultaneous rectal dose sparing via radiation shielding.

D Brivio1, P L Nguyen, E Sajo, W Ngwa, P Zygmanski.   

Abstract

We investigate via Monte Carlo simulations a new 125I brachytherapy treatment technique for high-risk prostate cancer patients via injection of Au nanoparticle (AuNP) directly into the prostate. The purpose of using the nanoparticles is to increase the therapeutic index via two synergistic effects: enhanced energy deposition within the prostate and simultaneous shielding of organs at risk from radiation escaping from the prostate. Both uniform and non-uniform concentrations of AuNP are studied. The latter are modeled considering the possibility of AuNP diffusion after the injection using brachy needles. We study two extreme cases of coaxial AuNP concentrations: centered on brachy needles and centered half-way between them. Assuming uniform distribution of 30 mg g-1 of AuNP within the prostate, we obtain a dose enhancement larger than a factor of 2 to the prostate. Non-uniform concentration of AuNP ranging from 10 mg g-1 and 66 mg g-1 were studied. The higher the concentration in a given region of the prostate the greater is the enhancement therein. We obtain the highest dose enhancement when the brachytherapy needles are coincident with AuNP injection needles but, at the same time, the regions in the tail are colder (average dose ratio of 0.7). The best enhancement uniformity is obtained with the seeds in the tail of the AuNP distribution. In both uniform and non-uniform cases the urethra and rectum receive less than 1/3 dose compared to an analog treatment without AuNP. Remarkably, employing AuNP not only significantly increases dose to the target but also decreases dose to the neighboring rectum and even urethra, which is embedded within the prostate. These are mutually interdependent effects as more enhancement leads to more shielding and vice-versa. Caution must be paid since cold spot or hot spots may be created if the AuNP concentration versus seed position is not properly distributed respect to the seed locations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28140338      PMCID: PMC5378384          DOI: 10.1088/1361-6560/aa5bc7

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  34 in total

1.  In vivo assembly of nanoparticle components to improve targeted cancer imaging.

Authors:  Steven D Perrault; Warren C W Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Experimental and Monte Carlo determination of the TG-43 dosimetric parameters for the model 9011 THINSeed brachytherapy source.

Authors:  R M Kennedy; S D Davis; J A Micka; L A DeWerd
Journal:  Med Phys       Date:  2010-04       Impact factor: 4.071

3.  Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy.

Authors:  Rajiv Kumar; Jodi Belz; Stacey Markovic; Tej Jadhav; William Fowle; Mark Niedre; Robert Cormack; Mike G Makrigiorgos; Srinivas Sridhar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-01       Impact factor: 7.038

4.  Impact of beam quality on megavoltage radiotherapy treatment techniques utilizing gold nanoparticles for dose enhancement.

Authors:  Panagiotis Tsiamas; Bo Liu; Fulya Cifter; Wilfred F Ngwa; Ross I Berbeco; Constantin Kappas; Kiriaki Theodorou; Karen Marcus; Mike G Makrigiorgos; Erno Sajo; Piotr Zygmanski
Journal:  Phys Med Biol       Date:  2013-01-10       Impact factor: 3.609

5.  Low-Z linac targets for low-MV gold nanoparticle radiation therapy.

Authors:  P Tsiamas; P Mishra; F Cifter; R I Berbeco; K Marcus; E Sajo; P Zygmanski
Journal:  Med Phys       Date:  2014-02       Impact factor: 4.071

Review 6.  Targeting nanoparticles to cancer.

Authors:  M Wang; M Thanou
Journal:  Pharmacol Res       Date:  2010-04-07       Impact factor: 7.658

7.  Current clinical presentation and treatment of localized prostate cancer in the United States.

Authors:  Usama Mahmood; Lawrence B Levy; Paul L Nguyen; Andrew K Lee; Deborah A Kuban; Karen E Hoffman
Journal:  J Urol       Date:  2014-06-12       Impact factor: 7.450

8.  Developing a nanoparticle test for prostate cancer scoring.

Authors:  Qun Huo; Sally A Litherland; Shannon Sullivan; Hillari Hallquist; David A Decker; Inoel Rivera-Ramirez
Journal:  J Transl Med       Date:  2012-03-09       Impact factor: 5.531

Review 9.  The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy.

Authors:  L Sancey; F Lux; S Kotb; S Roux; S Dufort; A Bianchi; Y Crémillieux; P Fries; J-L Coll; C Rodriguez-Lafrasse; M Janier; M Dutreix; M Barberi-Heyob; F Boschetti; F Denat; C Louis; E Porcel; S Lacombe; G Le Duc; E Deutsch; J-L Perfettini; A Detappe; C Verry; R Berbeco; K T Butterworth; S J McMahon; K M Prise; P Perriat; O Tillement
Journal:  Br J Radiol       Date:  2014-07-03       Impact factor: 3.039

10.  Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial.

Authors:  Shady Kotb; Alexandre Detappe; François Lux; Florence Appaix; Emmanuel L Barbier; Vu-Long Tran; Marie Plissonneau; Hélène Gehan; Florence Lefranc; Claire Rodriguez-Lafrasse; Camille Verry; Ross Berbeco; Olivier Tillement; Lucie Sancey
Journal:  Theranostics       Date:  2016-01-20       Impact factor: 11.556

View more
  2 in total

1.  A detailed Monte Carlo evaluation of 192Ir dose enhancement for gold nanoparticles and comparison with experimentally measured dose enhancements.

Authors:  Tara Gray; Nema Bassiri; Shaquan David; Devanshi Yogeshkumar Patel; Sotirios Stathakis; Neil Kirby; Kathryn M Mayer
Journal:  Phys Med Biol       Date:  2020-07-06       Impact factor: 3.609

2.  Intercomparison of Monte Carlo calculated dose enhancement ratios for gold nanoparticles irradiated by X-rays: Assessing the uncertainty and correct methodology for extended beams.

Authors:  H Rabus; W B Li; C Villagrasa; J Schuemann; P A Hepperle; L de la Fuente Rosales; M Beuve; S Di Maria; A P Klapproth; C Y Li; F Poignant; B Rudek; H Nettelbeck
Journal:  Phys Med       Date:  2021-03-23       Impact factor: 2.685

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.